Keros Therapeutics, Inc. (KROS) Stock

Keros Therapeutics, Inc. (KROS) is a Healthcare stock trading at $10.67 (as of 2026-06-18), with a market capitalization of $222.66M and a trailing P/E of -4.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing and commercializing treatments for patients with hematological and musculoskeletal disorders. Its lead candidate KER-050 targets cytopenias in myelodysplastic syndromes and myelofibrosis, while KER-047 is in Phase 1 for anemia and KER-012 is in Phase 1 for disorders associated with bone loss and pulmonary arterial hypertension.

Valuation — source: SEC EDGAR (first-party)
Price	$10.67
Market Cap	$222.66M
P/E Ratio	-4.2
EV / EBITDA	0.7
Price / Book	0.74
Price / Sales	6.45
DCF Value (model)	$106.13
DCF Upside vs Price	894.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$243.86M
Net Margin	35.7%
Return on Equity	-29.8%
Current Ratio	22.62
Revenue Growth (YoY)	6769.4%
EPS Growth (YoY)	-146.8%
FCF Growth (YoY)	-165.1%

Financial Health — source: SEC EDGAR
Altman Z-Score	4.05 (safe)

Valuation vs Sector & Industry
Stock P/E	-4.2
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-120.2%
vs Industry	-124.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($31.06M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Jasbir S. Seehra
Employees	163
Country	US
IPO Date	2020-04-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.